Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Charles River Laboratories Announces First-Quarter 2022 Results: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Announces First-Quarter 2022 Results


Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2022. For the quarter, revenue was $913.9 million, an increase of 10.8% from $824.6

LivaNova Reports First-Quarter 2022 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova Reports First-Quarter 2022 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2022.



Financial Summary and Highlights1

Acadia Healthcare Reports First Quarter 2022 Results: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Reports First Quarter 2022 Results


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2022.



First Quarter Highlights




  • Revenue totaled $616.7 million, an

ICON plc to present at the BofA Securities 2022 Healthcare Conference: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON plc to present at the BofA Securities 2022 Healthcare Conference


ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the BofA Securities

Chemed Corporation to Present at the Bank of America Merrill Lynch 2022 Health Care Conference:
Chemed Corporation to Present at the Bank of America Merrill Lynch 2022 Health Care Conference


Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Merrill Lynch 2022 Health Care Conference on Tuesday, May 10, 2022, at 9:20 AM (PDT) at the

Premier, Inc. Reports Fiscal-Year 2022 Third-Quarter Results: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Reports Fiscal-Year 2022 Third-Quarter Results


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2022 third quarter ended March 31, 2022.



"As we

COSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW(R) TO ALL COUNTRIES EXCEPT CANADA
COSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW(R) TO ALL COUNTRIES EXCEPT CANADA
COSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW(R) TO ALL COUNTRIES EXCEPT CANADA
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it

Novocure Reports First Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Reports First Quarter 2022 Financial Results


Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427005801/en/



Vifor Fresenius Medical Care Renal Pharma (VFMCRP)

Straumann Group reports very strong first quarter
Straumann Group reports very strong first quarter
Straumann Group reports very strong first quarter
ICON Reports First Quarter 2022 Results: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON Reports First Quarter 2022 Results


ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today reported its financial results for the first quarter ended March 31, 2022.



CEO Dr. Steve

Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets


Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc (“Valo”) have launched LogicaTM, an artificial intelligence (AI) powered drug solution that directly translates

Chemed Reports First-Quarter 2022 Results:
Chemed Reports First-Quarter 2022 Results


Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest

QIAGEN übertrifft Prognose für Q1 2022 mit starkem Umsatzwachstum von 14% (CER) bei Nicht-COVID-Produkten und erhöht Ausblick für das Gesamtjahr
QIAGEN übertrifft Prognose für Q1 2022 mit starkem Umsatzwachstum von 14% (CER) bei Nicht-COVID-Produkten und erhöht Ausblick für das Gesamtjahr


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Ergebnisse für das erste Quartal 2022 und eine Anhebung des Ausblicks für das Gesamtjahr 2022 bekannt.



Der Konzernumsatz

QIAGEN exceeds outlook for Q1 2022, delivers strong 14% CER sales growth from non-COVID products and increases full-year outlook
QIAGEN exceeds outlook for Q1 2022, delivers strong 14% CER sales growth from non-COVID products and increases full-year outlook


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the first quarter of 2022 and increased the outlook for full-year 2022.



Net sales for Q1 2022 rose 11% (+15% CER)

94th Vifor Pharma Group Annual General Meeting: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
94th Vifor Pharma Group Annual General Meeting


Regulatory News:



At today’s 94th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. The Annual General Meeting was

94. Generalversammlung der Vifor Pharma Gruppe: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
94. Generalversammlung der Vifor Pharma Gruppe


Regulatory News:



An der heutigen 94. ordentlichen Generalversammlung der Vifor Pharma AG haben die Aktionäre alle Anträge des Verwaltungsrats genehmigt. Die Generalversammlung fand erneut

DGAP-Adhoc: BB Biotech AG publishes its interim report
DGAP-Adhoc: BB Biotech AG publishes its interim report
DGAP-Adhoc: BB Biotech AG publishes its interim report
DGAP-News: BB BIOTECH AG: Increased investment level balanced by established core holdings
DGAP-News: BB BIOTECH AG: Increased investment level balanced by established core holdings
DGAP-News: BB BIOTECH AG: Increased investment level balanced by established core holdings
Premier, Inc. Declares Quarterly Cash Dividend: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Declares Quarterly Cash Dividend


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share of Class

QIAGEN N.V. to release results for Q1 2022 and hold Webcast
QIAGEN N.V. to release results for Q1 2022 and hold Webcast


QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release results for the first quarter of 2022 on Wednesday, April 27, at approximately 22:05 Frankfurt time

Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu


Today, Governor Chris Sununu (R-NH) joined Novocure for a ceremonial event commemorating the start of construction of its new flagship facility in the heart of downtown Portsmouth, New Hampshire

Acadia Healthcare Announces Date for First Quarter 2022 Earnings Release: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Announces Date for First Quarter 2022 Earnings Release


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its first quarter 2022 results on Tuesday, May 3, 2022, after the close of the market. Acadia will conduct a

Charles River Laboratories Schedules First-Quarter 2022 Earnings Release and Conference Call: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Schedules First-Quarter 2022 Earnings Release and Conference Call


Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2022 financial results on Wednesday, May 4th, before the market opens. A conference call has been scheduled to